The adjuvant treatment revolution for high-risk melanoma patients: Seminars in Cancer Biology

F. Spagnolo, A. Boutros, E. Tanda, P. Queirolo

Research output: Contribution to journalArticlepeer-review


The past 5 years have witnessed the results of many practice-changing studies that have dramatically improved the landscape of adjuvant therapy in patients with resected, high-risk melanoma. After a 20-year era of adjuvant interferon, the anti-CTLA-4 and anti-PD-1 immune-checkpoint inhibitors, and MAPK-directed targeted therapy brought a revolution into the adjuvant treatment of melanoma. These results came along with the practice-changing results of two large multicenter studies showing no benefit in terms of overall survival for completion lymph node dissection after positive sentinel node biopsy. In this review, we summarized the current state of the art of the adjuvant treatment of high-risk melanoma, with a view on future perspectives. © 2019
Original languageEnglish
Pages (from-to)283-289
Number of pages7
JournalSemin. Cancer Biol.
Publication statusPublished - 2019


  • Adjuvant
  • Immunotherapy
  • Melanoma
  • Neoadjuvant
  • Targeted therapy
  • alpha interferon
  • bevacizumab
  • dabrafenib
  • ipilimumab
  • nivolumab
  • pembrolizumab
  • trametinib
  • vemurafenib
  • adjuvant therapy
  • cancer staging
  • colitis
  • disease classification
  • distant metastasis free survival
  • drug efficacy
  • drug tolerability
  • fatigue
  • fever
  • Guillain Barre syndrome
  • high risk patient
  • human
  • lymph node dissection
  • lymph node metastasis
  • melanoma
  • myocarditis
  • nausea
  • overall survival
  • recurrence free survival
  • Review


Dive into the research topics of 'The adjuvant treatment revolution for high-risk melanoma patients: Seminars in Cancer Biology'. Together they form a unique fingerprint.

Cite this